Performance
September was a very strong month in most markets. The Benchmark (50% Eurostoxx, 30% Dax, 20% MDAX) gained 5.6%, this is the best month for the market since January 2012, where the BM started into the year with an 8.4% gain. Interestingly in September, the Eurostoxx outperformed both, DAX and MDAX.
The portfolio gained 4.9%, an underperformance of -0.7%. As discussed many times, I expect the portfolio to underperform in these markets, especially now when I own around 25% cash.
On a year-to-date basis, the portfolio is still ahead the benchmark with a gain of 26.6% against 17.5%.
The September performance was boosted significantly by two special events: The new buy out attempt for Rhoen Klinikum (+8.6%) and the minority buy out of EGIS (+30%). Other outperformers were Sol (+9.1%), Tonnelerie (+9.7%) G. Perrier (+9.5%), IGE (+7.1%). Underperformers were April (-1.3%) and Miko (+1.6%).
Nevertheless it is also important in my opinion to assess the own performance as objectively as possible with regard to skill and luck. Yes, 26.6% YTD sounds like a lot of skill. But in reality, there is a huge percentage of luck (in the form of BM performance) involved as well. European small and mid cap indices are performing like crazy (MDAX +30% YTDT, French mdi/small caps +22%, Italian Small/midcaps +31% and +37)%. As I am investing mostly into those small and midcaps, my performance doesn’t really look so good compared to those benchmarks. Yes, the decision to invest half of the portfolio in French and Italian small and midcaps was a good one, but the stock selection was rather mediocre and the cash allocation so far value destroying.
Portfolio activity
Portfolio activity was rather high with 3 transactions. I sold Pharmstandard after a few days because I overlooked an important aspect (record date). I increased the Rhoen Position and I added Trilogiq as a new “half” position. I am actually considering putting a “hard” limit on portfolio transactions per month in place (maybe 2 or 3)
Portfolio as of 30.09.2013:
Name |
Weight |
Perf. Incl. Div |
CORE VALUE |
|
|
Hornbach Baumarkt |
3.9% |
8.8% |
Miko |
2.5% |
4.3% |
Tonnellerie Frere Paris |
5.9% |
99.9% |
Vetropack |
3.8% |
7.3% |
Installux |
2.8% |
24.5% |
Poujoulat |
0.8% |
11.4% |
Cranswick |
5.5% |
44.7% |
April SA |
3.8% |
33.0% |
SOL Spa |
2.9% |
54.9% |
Gronlandsbanken |
1.8% |
12.3% |
G. Perrier |
3.7% |
50.3% |
IGE & XAO |
2.1% |
18.5% |
EGIS |
3.2% |
35.0% |
Thermador |
2.6% |
8.2% |
Trilogiq |
2.4% |
8.4% |
|
|
|
OPPORTUNITY |
|
|
KAS Bank NV |
4.9% |
45.7% |
SIAS |
5.1% |
75.1% |
Drägerwerk Genüsse D |
8.2% |
169.2% |
DEPFA LT2 2015 |
2.6% |
67.3% |
HT1 Funding |
4.1% |
49.9% |
EMAK SPA |
4.6% |
54.2% |
Rhoen Klinikum |
4.6% |
12.1% |
|
|
|
|
|
|
|
|
|
Short: Prada |
-0.9% |
-17.5% |
|
|
|
Short Lyxor Cac40 |
-1.1% |
-17.5% |
Short Ishares FTSE MIB |
-1.9% |
-15.4% |
|
|
|
Short CHF EUR |
0.2% |
6.4% |
|
|
|
Cash |
21.9% |
|
|
|
|
|
|
|
|
|
|
Core Value |
48.0% |
|
Opportunity |
33.9% |
|
Short+ Hedges |
-3.8% |
|
Cash |
21.9% |
|
|
100.0% |
|